Nesiritide (Natrecor, Scios Inc), human B-type natriuretic peptide, has hemodynamic effects that may be beneficial in pediatric patients after cardiac surgery. Experience with nesiritide and pediatrics is limited. The purpose of this study was to evaluate perioperative effects and safety of nesiritide in pediatric cardiothoracic surgery. Seventeen patients with congenital heart disease undergoing cardiac surgery were given a loading dose (1 μg/kg) while on cardiopulmonary bypass (constant flow) followed by continuous infusion for 24 hours (0.01 μg/kg/min x 6 hours, then 0.02 μg/kg/min x 18 hours). A 7% decrease in mean blood pressure was seen following nesiritide loading dose on cardiopulmonary bypass. No patient required intervention for hypotension while receiving nesiritide load or infusion. Nesiritide load during surgery and continuous infusion after cardiac surgery in pediatric patients resulted in no significant hemodynamic compromise.
- B-type natriuretic peptide
- Cardiac surgery
- Congenital heart disease
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine